RxDoctor Payments Data

Karen Eldridge

Family · Jellico, TNNPI 1053775973

Payments from drug & device makers

$2,485in general payments, 2019–2025

Across 124 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$604
  • AbbVie$327
  • Novo Nordisk$250
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$182
  • Amgen$134
  • E.r. Squibb & Sons, L.L.C.$115
  • plus $872 from 22 others

What the payments were for

  • Food & beverage$2,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,485 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$28,711
Medicare patients
71
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$70,656
MounjaroTirzepatide32$48,058
XifaxanRifaximin12$36,696
OzempicSemaglutide16$35,818
EliquisApixaban36$33,097
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,818
LinzessLinaclotide14$15,229
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$15,002
FarxigaDapagliflozin Propanediol12$9,029
Albuterol Sulfate HfaAlbuterol Sulfate70$2,382
Atorvastatin Calcium222$2,366
Pantoprazole Sodium126$1,714
Rosuvastatin Calcium195$1,712
Levothyroxine Sodium190$1,707
Irbesartan64$1,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$53$70,65665 claims
Lilly USA, LLCMounjaro$103$48,05832 claims
GSKTrelegy Ellipta, Anoro Ellipta$52$37,82034 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$182$36,69612 claims
Novo NordiskOzempic$250$35,81816 claims
PfizerEliquis$96$33,09736 claims
AbbVieLinzess, Synthroid$327$16,52627 claims
AstraZenecaFarxiga$604$9,02912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Jellico

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →